Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses

•Cholesterol efflux capacity (CEC) is inversely associated with CAD risk.•The CETP inhibitor TA-8995 increases total, abca1 and non-ABCA1 CEC.•TA-8995 increases pre-Beta1 HDL particles, the main acceptor for ABCA1 CEC.•Total CEC increase was associated with pre-Beta1 increase but not with HDL-C increase.